| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.007 | 0.8 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.0067 | 0.8 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | -0.0065 | 0.8 |
| mRNA | lapatinib | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | 0.0077 | 0.8 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | ouabain | CTRPv2 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | BRD-K71781559 | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.8 |
| mRNA | SB-525334 | CTRPv2 | pan-cancer | AAC | 0.0075 | 0.8 |